Skip to main content
Premium Trial:

Request an Annual Quote

Fluorotechnics to Raise $1.6M in Rights Offering

NEW YORK (GenomeWeb News) – Fluorotechnics today said that it is offering a one for five non-renouncable pro rata rights issue at A$.30 per share that it expects will bring in proceeds of A$1.8 million (US$1.6 million).

The Australian supplier of fluorescence and other protein detection technologies said that the shares are priced at a 14 percent discount to its closing price on the Australian Stock Exchange yesterday.

Fluorotechnics intends to use the proceeds for sales and marketing initiatives and as working capital.

It also noted that its sales expectations for fiscal year 2010 remain between $7 million and $10 million.

Earlier this year, the firm cut its forecast for 2009 revenues to around A$3.2 million (US$2.5 million) from its previous forecast of A$4 million.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.